**Voluntary Dose Management Programs**

The purpose of these dose management programs is to offer the prescriber a voluntary alternate dose that reduces drug waste without compromising the member’s health.

**Immunoglobulin Dose Adjustment Program**

The immunoglobulin dose adjustment program offers the prescriber an option to use adjusted body weight instead of the member’s actual body weight to calculate the immune globulin dose when clinically appropriate.

This is a voluntary program and is not meant to replace clinical decision making by the prescriber. This information should only be used as a guide. Patient-specific variables should be considered. Declining to use adjusted body weight for dosing will not impact the precertification request.

Where clinically appropriate and with provider agreement, immune globulins may be dosed based on adjusted body weight (AdjBW) in individuals whose actual body weight (ABW) is 20% higher than his or her ideal body weight (IBW). The dosing formulas used to calculate adjusted body weight are:

* IBW (males) = 50 kg + (2.3 kg for each inch over 5 feet)
* IBW (females) = 45.5 kg + (2.3 kg for each inch over 5 feet)
* Adjusted body weight = IBW + 0.4 (actual body weight – IBW)

Situations where dose adjustments may not apply to the member include:

* The individual is younger than 18 years of age
* The individual is less than 60 inches (5 feet) tall
* The dosing is based on a specific and measurable IgG level recommended for the indication requested
* The individual has been stable on current dose, and previous attempts to decrease or adjust the dose have resulted in worsening of symptoms or relapse
* Other patient-or indication-specific variables, or other factors per clinician’s judgement

List of drugs in scope

|  |  |
| --- | --- |
| Asceniv Bivigam Carimune NF Cutaquig Cuvitru Flebogamma DIF 5% Flebogamma DIF 10% Gammagard Gammagard S-DGammaked  | Gammaplex Gamunex-C Hizentra Hyqvia Octagam 5% Octagam 10% PanzygaPrivigenXembify |

**Dose Vial Rounding Program**

The dose vial rounding program offers the prescriber an option to decrease the originally requested dose by up to 10% to the nearest whole vial size for specific oncology and non-oncology therapy in eligible members, where clinically appropriate.

This is a voluntary program and is not meant to replace clinical decision making by the prescriber. This information should only be used as a guide. Patient-specific variables should be considered. Declining to use the rounded down dose will not affect the final determination of the precertification request.

The number of vials used based on the requested dose will be compared to the number of vials needed for a 10% or less reduction in the dose. If a 10% or less reduction allows for a reduction in the number of vials needed, the option to decrease the original dose will be discussed with the provider.

Situations where dose adjustments may not apply to the member include:

* If there is a greater than 10% change to nearest whole vial, then the originally requested dose will be identified as the appropriate dose.
* The medication is supplied in a multiple-dose vial
* Other patient-or indication-specific variables, or other factors per clinician’s judgement.

List of drugs in scope

|  |  |
| --- | --- |
| Oncology | Non-Oncology |
| AbraxaneActimmuneAdcetrisAlimtaAmerinetAsparlasAvastinBeleodaqBendekaBesponsaBicnuBlenrepBlincytoCamptosarClolarCosmegenCyramzaDacogenDarzalexDoxorubicin liposomalEloxatinElzonrisEmplicitiEnhertuErbitux | ErwinazeEthyolFolotynGranixHalavenHerceptinHerzumaImfinziInfugemIstodaxIxempra KitJevtanaKadcylaKanjintiKeytrudaKyprolisLumoxitiMargenzaMonjuviMutamycinMvasiMylotargNeupogenNipentNivestymOgivri | OncasparOntruzantOpdivoPadcevPolivyPoteligeoProleukinRiabniRiabniRituxanRuxienceRuxienceSarclisaSylvantTrazimeraTreandaTrisenoxTruximaVectibixVelcadeYervoyYondelisZaltrapZarxioZepzelcaZirabev | RemicadeAvsolaRenflexisInflectraIxifi |